$Telix Pharmaceuticals (TLX.US)$ Telix Pharmaceuticals (ASX: TLX, Nasdaq: TLX) has received FDA approval for Gozellix®, a next-generation PSMA-PET imaging agent for prostate cancer. The product is designed for PET scanning of PSMA positive lesions in men with suspected metastasis or recurrence.
Key features of Gozellix® include:
Extended shelf life up to 6 hours
Wider distribution radius compared to existing products
Enhanced efficiency and scheduling flexibility for scanning clinics
Expect...

$Telix Pharmaceuticals (TLX.US)$
FDA Green Lights Revolutionary Prostate Cancer Detection Tool: What Makes Gozellix a Game-Changer

$Telix Pharmaceuticals (TLX.US)$
Major Breakthrough: First PSMA-PET Imaging Agent Approved in Brazil's $330M Market

$Telix Pharmaceuticals (TLX.US)$
Telix's Game-Changing Isotope Technology Revolutionizes Cancer Treatment Production

$Telix Pharmaceuticals (TLX.US)$
Could This New Kidney Cancer Imaging Tool Transform Diagnosis? FDA Fast-Tracks Review

$Telix Pharmaceuticals (TLX.US)$
Could This New Prostate Cancer Treatment Change Patient Outcomes? Miami Trial Now Recruiting

$Telix Pharmaceuticals (TLX.US)$
Clinical Trial Success: Telix's Revolutionary Prostate Cancer Treatment Shows Promising Results

$Telix Pharmaceuticals (TLX.US)$
Inside Telix's Strategic $45M ImaginAb Acquisition: Next-Gen Cancer Treatment Pipeline Secured

$Telix Pharmaceuticals (TLX.US)$
Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
Positive
Strategic acquisition of next-generation therapeutic pipeline and technology platform
Access to state-of-the-art California research facility and expert team
Enhanced in-house capabilities in antibody engineering
Technology enables highly specific cancer targeting with improved efficiency
Potential for expansion into new therapy areas
Negative
Significant upf...